全文获取类型
收费全文 | 615篇 |
免费 | 72篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 7篇 |
妇产科学 | 4篇 |
基础医学 | 56篇 |
口腔科学 | 7篇 |
临床医学 | 64篇 |
内科学 | 84篇 |
皮肤病学 | 10篇 |
神经病学 | 43篇 |
特种医学 | 28篇 |
外科学 | 72篇 |
综合类 | 16篇 |
预防医学 | 116篇 |
眼科学 | 5篇 |
药学 | 62篇 |
中国医学 | 3篇 |
肿瘤学 | 112篇 |
出版年
2021年 | 20篇 |
2020年 | 4篇 |
2019年 | 13篇 |
2018年 | 13篇 |
2017年 | 12篇 |
2016年 | 10篇 |
2015年 | 13篇 |
2014年 | 19篇 |
2013年 | 16篇 |
2012年 | 27篇 |
2011年 | 22篇 |
2010年 | 12篇 |
2009年 | 9篇 |
2008年 | 35篇 |
2007年 | 27篇 |
2006年 | 30篇 |
2005年 | 30篇 |
2004年 | 11篇 |
2003年 | 19篇 |
2002年 | 20篇 |
2001年 | 6篇 |
2000年 | 10篇 |
1999年 | 7篇 |
1997年 | 8篇 |
1996年 | 9篇 |
1994年 | 6篇 |
1992年 | 25篇 |
1991年 | 18篇 |
1990年 | 16篇 |
1989年 | 18篇 |
1988年 | 22篇 |
1987年 | 9篇 |
1986年 | 8篇 |
1985年 | 10篇 |
1984年 | 12篇 |
1983年 | 10篇 |
1982年 | 7篇 |
1981年 | 7篇 |
1979年 | 10篇 |
1978年 | 4篇 |
1976年 | 4篇 |
1974年 | 8篇 |
1973年 | 6篇 |
1972年 | 7篇 |
1971年 | 4篇 |
1970年 | 10篇 |
1969年 | 10篇 |
1968年 | 8篇 |
1967年 | 6篇 |
1947年 | 4篇 |
排序方式: 共有691条查询结果,搜索用时 15 毫秒
21.
22.
23.
Jonathan Covault Timothy Pond Richard Feinn Albert J. Arias Cheryl Oncken Henry R. Kranzler 《Psychopharmacology》2014,231(17):3609-3618
Rationale
Preclinical studies support the hypothesis that endogenous neuroactive steroids mediate some effects of alcohol.Objectives
The aim of this study was to examine the effect of dutasteride inhibition of 5α-reduced neuroactive steroid production on subjective responses to alcohol in adult men.Methods
Using a within-subject factorial design, 70 men completed four randomly ordered monthly sessions in which pretreatment with 4 mg dutasteride or placebo was paired with a moderate dose of alcohol (0.8 g/kg) or placebo beverage. The pharmacologic effect of dutasteride was measured by an assay of serum androstanediol glucuronide. Self-reports of alcohol effects were obtained at 40-min intervals following alcohol administration using the Biphasic Alcohol Effects Scale (BAES) and the Alcohol Sensation Scale (SS). We used linear mixed models to examine the effects of dutasteride and alcohol on BAES and SS responses and the interaction of dutasteride with the GABRA2 alcohol dependence-associated polymorphism rs279858. We also examined whether exposure to dutasteride influenced drinking in the weeks following each laboratory session.Results
A single 4-mg dose of dutasteride produced a 70 % reduction in androstanediol glucuronide. Dutasteride pretreatment reduced alcohol effects on the BAES sedation and SS anesthesia scales. There was no interaction of dutasteride with rs279858. Heavy drinkers had fewer heavy drinking days during the 2 weeks following the dutasteride sessions and fewer total drinks in the first week after dutasteride.Conclusions
These results provide evidence that neuroactive steroids mediate some of the sedative effects of alcohol in adult men and that dutasteride may reduce drinking, presumably through its effects on neuroactive steroid concentrations. 相似文献24.
25.
Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells 总被引:16,自引:0,他引:16
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Carter BZ Gronda M Wang Z Welsh K Pinilla C Andreeff M Schober WD Nefzi A Pond GR Mawji IA Houghten RA Ostresh J Brandwein J Minden MD Schuh AC Wells RA Messner H Chun K Reed JC Schimmer AD 《Blood》2005,105(10):4043-4050
We tested the effects of small-molecule XIAP antagonists based on a polyphenylurea pharmacophore on cultured acute myelogenous leukemia (AML) cell lines and primary patient samples. X-linked inhibitor of apoptosis protein (XIAP) antagonist N-[(5R)-6-[(anilinocarbonyl)amino]-5-((anilinocarbonyl){[(2R)-1-(4-cyclohexylbutyl)pyrrolidin-2-yl]methyl}amino)hexyl]-N-methyl-N'-phenylurea (1396-12), but not a structurally related control compound, induced apoptosis of primary leukemia samples with a lethal dose (LD50) of less than 10 microM in 16 of 27 (60%) samples. In contrast, XIAP antagonist 1396-12 was not lethal to the normal hematopoietic cells in short-term cytotoxicity assays. Response of primary AML specimens to XIAP inhibitor correlated with XIAP protein levels, with higher levels of XIAP associated with sensitivity. The XIAP antagonist 1396-12 induced activation of downstream caspases 3 and 7 prior to the activation of upstream caspase 8 and caspase 9. Apoptosis induction was also independent of B-cell lymphoma protein-2 (Bcl-2) or caspase 8, indicative of a downstream effect on apoptotic pathways. Thus, polyphenylurea-based XIAP antagonsists directly induce apoptosis of leukemia cells and AML patient samples at low micromolar concentrations through a mechanism of action distinct from conventional chemotherapeutic agents. 相似文献
26.
27.
28.
Ignacio Duran Sebastien J Hotté Holger Hirte Eric X Chen Martha MacLean Sandra Turner Lixia Duan Gregory R Pond Chetan Lathia Scott Walsh John J Wright Janet Dancey Lillian L Siu 《Clinical cancer research》2007,13(16):4849-4857
PURPOSE: Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors with antiproliferative and antiangiogenic activities. Given their inhibitory target profile and efficacy as single agents, the combination of these drugs is of considerable interest in solid malignancies. This study aimed to determine the recommended phase II dose of this targeted combination, their toxicity profile, pharmacokinetic interaction, and preliminary clinical activities. EXPERIMENTAL DESIGN: Sorafenib was administered alone for a 1-week run-in period, and then both drugs were given together continuously, with every 28 days considered as a cycle. Three dose levels were assessed. RESULTS: Seventeen patients with advanced solid tumors received 75 cycles of treatment. The most frequent adverse events of all grades were constitutional and gastrointestinal in nature followed by electrolytes and dermatologic toxicities. Fatigue was the most common adverse event (17 patients; 100%) followed by diarrhea (15 patients; 88%), hypophosphatemia (13 patients; 76%), and acneiform rash (12 patients; 71%). These adverse events were predominantly mild to moderate. The recommended phase II dose of this combination was determined as 400 mg twice daily sorafenib and 150 mg daily erlotinib. Pharmacokinetic analysis revealed no significant effect of erlotinib on the pharmacokinetic profile of sorafenib. Among 15 evaluable patients, 3 (20%) achieved a confirmed partial response and 9 (60%) had stable disease as best response. CONCLUSIONS: Sorafenib and erlotinib are well tolerated and seem to have no pharmacokinetic interactions when administered in combination at their full single-agent recommended doses. This well tolerated combination resulted in promising activity that needs further validation in phase II studies. 相似文献
29.
Dental patients often give a medical history that suggests the possibility of a coagulopathy from drugs, with a corresponding risk for prolonged bleeding during and following an invasive procedure. Identification of patients who may be prone to oral bleeding requires specific medical history information and the proper use of laboratory tests. Some NSAIDs are reported to cause prolonged oral bleeding, but scientific evidence is lacking. Likewise, the risk of oral bleeding from anticoagulants such as warfarin is often over stated, and unnecessary adjustment of NSAID or warfarin dosage puts patients at risk for significant morbidity and mortality. Some commonly employed laboratory tests such as the prothrombin time provide helpful information when used in the appropriate setting, but others, such as the bleeding time test, provide little or no predictive value in the determination of patients at risk for oral bleeding. Dental management of patients with potential coagulopathies from medications requires an understanding of basic principles of coagulation. The vast majority of these patients can be managed in the community setting without risk and without alteration of anticoagulant drug regimes. 相似文献
30.
Carol A Townsley Kelvin K Chan Gregory R Pond Christine Marquez Lillian L Siu Sharon E Straus 《BMC cancer》2006,6(1):34